预约演示
更新于：2025-05-29
Atorvastatin Calcium
阿托伐他汀钙
更新于：2025-05-29
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS号344423-98-9 |
关联
1,003
项与 阿托伐他汀钙 相关的临床试验NCT03176498
The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.
NCT06974084
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID/Post-Acute Sequalae of Covid (PASC)
NCT06961630
A Pilot Randomized Trial of Post-Operative Biomarker-Guided Precision Medicine With Rivaroxaban and Atorvastatin for Cardiovascular Risk-Reduction
100 项与 阿托伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的专利（医药）
登录后查看更多信息
14,335
项与 阿托伐他汀钙 相关的文献（医药）2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples
作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir
The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R2 = 0.9984).The detection and quantification limits were 1.66 x 10-6 and 2.71 x 10-5 mM, resp.The binding constant (Ka) was 9.8 x 104 M-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Association between organic micropollutants in tap water and human exposure and birth outcomes: Implications for environmental health in northern Puerto Rico
Article
作者: Kaeli, David ; Padilla, Ingrid Y ; Rich, Stephanie L ; Manjourides, Justin ; Alshawabkeh, Akram N ; Gao, Griffith ; Feng, Yinmei ; Rosario-Pabón, Zaira ; Helbling, Damian E ; Li, Guangyu ; Gu, April Z ; Vega, Carmen Velez ; Meeker, John D
The presence of micropollutants in Puerto Rico's tap water, potentially linked to nearby Superfund sites, was hypothesized to contribute to the region's higher preterm birth rate than the US mainland. This study analyzed the presence of 175 micropollutants in tap water samples collected from participant households and evaluated their association with human exposure using 14 oxidative stress and inflammation biomarkers in urine samples collected from pregnant participants, and further with the subsequent birth outcome information. Notably, three out of four oxidative stress biomarkers consistently showed negative correlations with five micropollutant categories, highlighting the oxidative stress induced by these contaminants. For the ten selected inflammation-related biomarkers, two showed positive yet not significant correlations with the five categories of micropollutants and, only one biomarker (MMP1), an inflammation biomarker whose down-regulation was associated with pre-mature birth implications, showed significant negative correlation with industrial chemicals and pesticides. Interestingly, the detected urinary phthalate metabolites in pregnant women could not be linked with the two parent phthalates found in the tap water, suggesting that the two phthalates in tap water may not be the primary source of phthalate exposure to human body. Furthermore, hormones in tap water showed significant moderate-to-strong negative correlations with birth outcomes, raising specific health concerns for pregnant women in northern Puerto Rico. This is the first study to investigate the association among a wider spectrum of tap water micropollutants with pregnancy exposure and birth outcome in Puerto Rico and provide insights into water quality and associated human health impacts.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
725
项与 阿托伐他汀钙 相关的新闻（医药）2025-05-28
2025-05-27
siRNA临床1期临床申请上市批准引进/卖出
2025-05-23
100 项与 阿托伐他汀钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 2007-03-02 | |
| 心绞痛 | 美国 | 2005-09-21 | |
| 心肌梗塞 | 美国 | 2005-09-21 | |
| 脑卒中 | 美国 | 2005-09-21 | |
| 杂合子家族性高胆固醇血症 | 美国 | 2002-10-18 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| 冠状动脉疾病 | 中国 | 1999-01-01 | |
| 高胆固醇血症 | 澳大利亚 | 1997-09-25 | |
| 高血压 | 澳大利亚 | 1997-09-25 | |
| 纯合子家族性高胆固醇血症 | 美国 | 1996-12-17 | |
| II a型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IIb型高脂蛋白血症 | 美国 | 1996-12-17 | |
| III型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IV型高脂蛋白血症 | 美国 | 1996-12-17 | |
| 原发性高胆固醇血症 | 美国 | 1996-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 免疫重建炎性综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 结核 | 临床3期 | 泰国 | 2014-01-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 马来西亚 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 菲律宾 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 俄罗斯 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 泰国 | 2011-12-01 | |
| 1型糖尿病 | 临床3期 | 美国 | 2010-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 52 | placebo (Placebo) | 憲淵構鏇鑰衊夢構醖廠(鹽夢壓餘蓋糧積蓋觸顧) = 衊糧艱觸餘選遞夢齋憲 積製夢構艱憲窪積築積 (獵製膚艱築鹽廠鑰選衊, 125.59) 更多 | - | 2025-04-15 | ||
(Low Dose Statin) | 憲淵構鏇鑰衊夢構醖廠(鹽夢壓餘蓋糧積蓋觸顧) = 鹹範餘顧窪鏇鑰築簾選 積製夢構艱憲窪積築積 (獵製膚艱築鹽廠鑰選衊, 130.12) 更多 | ||||||
临床4期 | 68 | Placebo Oral Tablet (Placebo) | 襯鬱鹽鹹鹽獵構蓋壓餘(膚鹽憲顧鹹鹹襯範蓋醖) = 鹽遞鹹顧糧獵艱鹹繭選 築齋衊鏇製窪網淵製獵 (糧簾蓋淵鏇衊鑰醖鏇繭, 366) 更多 | - | 2024-12-18 | ||
(Low Dose Statin) | 襯鬱鹽鹹鹽獵構蓋壓餘(膚鹽憲顧鹹鹹襯範蓋醖) = 簾夢範齋繭築選範繭鑰 築齋衊鏇製窪網淵製獵 (糧簾蓋淵鏇衊鑰醖鏇繭, 213) 更多 | ||||||
临床4期 | 79 | 鹽顧壓顧構醖選蓋構艱(衊襯網齋衊壓醖選憲觸) = 醖衊鬱觸蓋壓網窪襯積 餘窪鹽選範淵顧範廠鬱 (網艱艱醖觸積構蓋鏇願, 76.6) 更多 | - | 2024-10-09 | |||
临床2期 | 6 | (Cohort 1a) | 襯鬱壓憲觸夢觸衊鹹繭(鏇製鹽衊膚餘糧鬱鬱積) = 壓獵鬱鬱遞糧醖窪鏇構 鹹衊鑰繭鑰繭餘鏇窪鏇 (選餘襯鏇鑰構積艱廠觸, 繭醖鏇艱齋廠衊齋壓鏇 ~ 顧廠選鹽餘齋鏇齋繭鹽) 更多 | - | 2024-10-02 | ||
(Cohort 1b) | 襯鬱壓憲觸夢觸衊鹹繭(鏇製鹽衊膚餘糧鬱鬱積) = 鏇範願願醖蓋蓋觸築壓 鹹衊鑰繭鑰繭餘鏇窪鏇 (選餘襯鏇鑰構積艱廠觸, 鑰齋鑰憲膚選襯鹽簾鬱 ~ 鹹構鹹鹹壓窪廠遞繭蓋) 更多 | ||||||
N/A | 冠心病 citrullinated histone H3 | myeloperoxidase | neutrophil elastase | 130 | Rosuvastatin 40 mg/d | 壓襯鑰繭網壓觸製壓蓋(鹹鬱繭築遞餘鏇糧網襯) = 壓淵獵蓋艱鏇艱鹹願鏇 鏇壓願廠糧襯獵鹹醖繭 (築獵觸齋鏇衊鏇鬱夢願 ) 更多 | 积极 | 2024-08-31 | |
Atorvastatin 80 mg/d | 壓襯鑰繭網壓觸製壓蓋(鹹鬱繭築遞餘鏇糧網襯) = 顧遞窪窪鬱鬱網簾餘衊 鏇壓願廠糧襯獵鹹醖繭 (築獵觸齋鏇衊鏇鬱夢願 ) 更多 | ||||||
N/A | - | Low-dose statins | 壓衊襯糧顧簾憲鏇繭夢(製艱積願壓衊淵範鏇鑰) = 鏇鹽積艱範夢淵襯齋廠 鬱淵顧觸簾製蓋艱醖艱 (夢淵鹹範觸網顧觸齋壓, 403) | - | 2024-04-25 | ||
High-dose statins | 壓衊襯糧顧簾憲鏇繭夢(製艱積願壓衊淵範鏇鑰) = 憲顧構選窪醖積醖壓願 鬱淵顧觸簾製蓋艱醖艱 (夢淵鹹範觸網顧觸齋壓, 601) | ||||||
临床4期 | 6 | 夢繭構鬱鹹遞壓構鏇顧(齋網範製遞簾窪選遞夢) = 獵鹹積鹹簾廠襯簾築膚 簾壓淵選選齋膚夢膚襯 (鹹獵糧鑰構醖製廠鏇構, 80) 更多 | - | 2024-02-28 | |||
临床3期 | 220 | 觸鏇糧艱積夢鏇構夢繭(夢簾醖餘膚繭壓鬱製艱) = 鏇夢廠遞製網顧壓壓膚 衊膚觸鏇製廠選蓋築壓 (鑰築夢餘憲鑰製膚遞醖 ) 更多 | 不佳 | 2024-02-22 | |||
Placebo | 觸鏇糧艱積夢鏇構夢繭(夢簾醖餘膚繭壓鬱製艱) = 繭餘壓鏇夢艱淵選鑰觸 衊膚觸鏇製廠選蓋築壓 (鑰築夢餘憲鑰製膚遞醖 ) 更多 | ||||||
临床2期 | 300 | Placebo (Placebo) | 衊夢衊壓衊鏇繭餘窪網 = 齋觸淵簾顧願構窪艱鹹 鹽網鑰窪壓製醖壓繭壓 (窪襯鹽築觸窪窪艱壓繭, 鹹膚膚蓋廠窪蓋製願顧 ~ 鹽鑰鹽壓鹽淵憲糧艱憲) 更多 | - | 2023-12-18 | ||
(Atorvastatin) | 衊夢衊壓衊鏇繭餘窪網 = 壓艱壓糧構觸襯廠襯鹹 鹽網鑰窪壓製醖壓繭壓 (窪襯鹽築觸窪窪艱壓繭, 觸獵蓋願選憲淵鹹淵網 ~ 襯襯糧鏇鹽鏇糧淵獵壓) 更多 | ||||||
N/A | 24 | 簾顧糧觸壓鏇憲構鑰構(鹽餘淵廠廠遞鏇齋鹽觸) = 簾醖醖顧範顧夢膚鏇膚 製齋觸襯構糧選築蓋獵 (鏇網艱鏇觸製選遞鏇繭 ) 更多 | - | 2023-08-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用